Efficacy and safety of belantamab mafodotin vs pomalidomide plus dexamethasone in relapsed/refractory multiple myeloma
Efficacy and safety of belantamab mafodotin vs pomalidomide plus dexamethasone in relapsed/refractory multiple myeloma
Belamaf monotherapy induced rapid responses without unexpected toxicity in relapsed or refractory light chain amyloidosis
Triplets for newly diagnosed unfit AML patients could be feasible with substantial venetoclax reduction
First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer
The parotid gland; an unusual site of colorectal cancer metastasis
ASCO's efforts to improve global cancer care through the years
US NCI's global health initiatives at ASCO 2023
The Lancet Commission on Women and Cancer
Advancing breast cancer treatment in Uganda by improving molecular testing
Somatic mutation profile of breast cancer in Uganda
Real-world behavioural restrictional practices of cancer patients
iCCaRE Consortium for Black Men: Second Discussion